Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED).

A detailed analysis of these effects will undoubtedly be possible with the highly selective PDE5 inhibitors now available.

He noted that in controlled studies, like the ones he previously conducted, PDE5 inhibitors and nitrates were administered "very close to each other, on purpose," yet this probably doesn't reflect ...

Phosphodiesterase 5 inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to an NIH study.

A new study published in The New England Journal of Medicine showed that nerandomilast at doses of 18 mg or 9 mg twice day delayed the development of disease in people with progressive ...

There is a class of drugs called “Phosphodiesterase-5 inhibitors” (PDE5 inhibitors.) Such drugs in this class are known as sildenafil, vardenafil, tadalafil, and avanafil.1 These drugs all work by ...

A new study shows for the first time that vardenafil, a PDE5 inhibitor, is more efficacious when used on-demand in men with erectile dysfunction, supporting a shift towards on-demand dosing with ...

Three drugs widely prescribed for erectile dysfunction are unlikely to increase risk of malignant melanoma, according to a new study.

In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or PDE5, inhibitors were associated with better survival and outcomes compared with ...

Patients with pulmonary arterial hypertension at intermediate risk who switched from phosphodiesterase type 5 inhibitors to riociguat experienced clinical improvement at 24 weeks, according to ...

Meiji Seika Pharma initiated Phase II clinical trial of ME3183, a selective PDE4 inhibitor, in patients with plaque psoriasis in the US and Canada.

Meiji's highly-potent selective PDE4 inhibitor, ME3183, met the primary endpoint in Phase 2 study in psoriasis patients in US and Canada.